Research Article

Ganglion cell complex analysis in thalassemia major patients measured by optical coherence tomography

Volume: 1 Number: 2 July 27, 2021
  • Semra Koca

Ganglion cell complex analysis in thalassemia major patients measured by optical coherence tomography

Abstract

To analyze the changes in ganglion cell complex (GCC), peripapillary retinal nerve fiber layer (RNFL) thickness and central macular thickness (CMT) on spectral domain optical coherence tomography (OCT) in patients with thalassemia major. Forty one eyes of 41 patients with thalassemia major and 41 eyes of 41 healthy subjects were included in this prospective and comparative study. Peripapillary RNFL thickness, CMT and macular GCC thickness were evaluated with OCT (Cirrus HD-OCT 5000Carl Zeiss Meditec, Inc, Dublin, CA, USA) in all patients and healthy controls. Additionally, disease duration, serum ferritin level, hemoglobin concentration, the dosage and duration of chelation therapy, count of transfusion, patient’s weight were analyzed in thalassemia major group. RNFL thickness values were lower in the thalassemia patients but the difference was not statistically significant (except superior quadrant) and there was no significant differences in the mean CMT measurements. GCC thickness was thinner in all areas ( average, superior, inferior, superior-temporal, inferior-temporal, superior-nasal, inferior-nasal) but only the thinning in the inferior-temporal was statistically significant. GCC and RNFL thickness changes occur earlier than CMT changes in β-thalassemia major patients. GCC thickness measurements can be used for follow-up in combination with other diagnostic methods.

Keywords

References

  1. Provan D, Singer CR, Baglin T, Dokal I. Oxford handbook of clinical haematology. Oxford: Oxford University Press; 2009
  2. Liaska A, Petrou P, Georgakopoulos CD, Diamanti R. β-Thalassemia and ocular implications: a systematic review. BMC Ophthalmol. 2016;16:102. doi: 10.1186/s12886-016-0285-2.
  3. Taneja R, Malik P, Sharma M, Agarwal MC. Multiple transfused thalassemia major: ocular manifestations in a hospital-based population. Indian J Ophthalmol 2010;58(2):125-30. doi: 10.4103/0301-4738.60083.
  4. Taher A, Bashshur Z, Shamseddeen WA, Abdulnour RE, Aoun E, Koussa S. et al. Ocular findings among thalassemia patients. Am J Ophthalmol 2006;142:704-5. doi: 10.1016/j.ajo.2006.04.030.
  5. Bollig C, Schell LK, Rücker G, Allert R, Motschall E, Niemeyer CM et al. Deferasirox for managing iron overload in people with thalassaemia. Cochrane Database Syst Rev. 2017;15;8(8):CD007476. doi: 10.1002/14651858.CD007476.pub3.
  6. Kontoghiorghe CN, Kontoghiorghes GJ. Efficacy and safety ofiron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes. Drug Des DevTher. 2016;10:465-481. doi: 10.2147/DDDT.S79458.
  7. Bhoiwala DL, Dunaief JL. Retinal abnormalities in β-thalassemia major. Surv Ophthalmol. 2016 Jan-Feb;61(1):33-50. doi: 10.1016/j.survophthal.2015.08.005.
  8. Jafari R, Heydarian S, Karami H, Shektaei MM, Dailami KN, Amiri AA. et al. Ocular abnormalities in multi-transfused beta-thalassemia patients. Indian J Ophthalmol. 2015 Sep;63(9):710-5. doi: 10.4103/0301-4738.170986.

Details

Primary Language

English

Subjects

Health Care Administration

Journal Section

Research Article

Authors

Semra Koca This is me
Türkiye

Publication Date

July 27, 2021

Submission Date

June 13, 2021

Acceptance Date

June 25, 2021

Published in Issue

Year 2021 Volume: 1 Number: 2

Vancouver
1.Semra Koca. Ganglion cell complex analysis in thalassemia major patients measured by optical coherence tomography. Health Sci. Q. [Internet]. 2021 Jul. 1;1(2):63-8. Available from: https://izlik.org/JA46EJ22RY